Approved and Emerging Hormone Therapies Offer New Hope for Obesity Treatment

Obesity is a global public health crisis, significantly increasing the risk of numerous comorbidities like type 2 diabetes, cardiovascular disease, and certain cancers. Despite lifestyle interventions, many individuals struggle with sustained weight loss, underscoring the critical need for effective pharmacological treatments. This comprehensive review aims to synthesize the current landscape of approved and emerging hormone-based anti-obesity medications, detailing their mechanisms, efficacy, and safety profiles.

The review highlighted that GLP-1 receptor agonists consistently achieve significant weight loss, with semaglutide 2.4 mg demonstrating an average body weight reduction of 15-17% in clinical trials. Dual GLP-1/GIP receptor agonists like tirzepatide showed even greater efficacy, leading to an impressive 20-22.5% mean weight loss at its highest dose. The article detailed how these medications primarily work by enhancing satiety, slowing gastric emptying, and improving glucose metabolism. Emerging therapies, including amylin analogs and melanocortin-4 receptor agonists, also showed promising results, often in combination with other agents, contributing to additional 5-10% weight reductions. While gastrointestinal side effects like nausea and vomiting were common, they were generally mild to moderate and transient, with discontinuation rates typically around 5-10%. The most significant finding is the paradigm shift towards highly effective hormone-based therapies, with tirzepatide achieving weight loss comparable to bariatric surgery in some individuals, marking a 2.5-fold improvement over earlier anti-obesity drugs.